Axsome Therapeutics (AXSM) recognizes Migraine and Headache Awareness Month alongside the Association of Migraine Disorders. In honor of this year’s theme, “Your Path to Better Days,” Axsome is supporting more than a dozen Miles for Migraine Run, Walk or Relax events across the U.S. throughout the month of June and beyond. Axsome is also sharing resources for patients and their loved ones affected by migraine.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Strong Growth Potential and Market Penetration Drive Buy Rating for Axsome Therapeutics
- Axsome Therapeutics price target lowered to $186 from $193 at RBC Capital
- Axsome Therapeutics: Buy Rating Affirmed Amid Promising Pipeline Developments and Strategic Focus
- Axsome Therapeutics Launches SYMBRAVO for Migraine Relief
- Axsome Therapeutics announces availability of SYMBRAVO in U.S.